Abstract

Dementia is a progressive and irreversible deterioration of cognition which has a significant impact on the person's activities of daily living and quality of life. Currently, there is no curative treatment of dementia and the treatment options currently used in clinical practice has limited therapeutic reach. Although there are ongoing clinical trials, this review article begins with the question of why statins are no longer clinically indicated in mild cognitive impairment or mild to moderate dementia? This review will explore the evidence in support and against the neuroprotective effects of statins in cognitive impairment. Whilst exploring the evidence around statins, there emerged a possibility of another molecule called cyclodextrin which could potentially not only be a more effective neuroprotective alternative to statins, but possibly an agent which could potentially improve the early or mild cognitive deficits. This literature review will hopefully support in formulating a potential research question for future clinical trials in the treatment of dementia.